Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons from the United States, France, and Japan

Journal of Law, Medicine and Ethics 39 (4):662-670 (2011)
  Copy   BIBTEX

Abstract

Post-industrial societies confront common problems in pharmaceutical industry-physician relations. In order to promote sales, drug firms create financial relationships that influence physicians' prescriptions and sometimes even reward physicians for prescribing drugs. Three main types exist: kickbacks, gifts, and financial support for professional activities. The prevalence of these practices has evolved over time in response to changes in professional codes, law, and markets. There are certainly differences among these types of ties, but all of them can compromise physicians' independent judgment and rational prescribing.Drug firms have paid kickbacks for prescribing drugs, purchasing drugs, switching brands prescribed, adding a drug to a hospital formulary, enrolling patients in post-marketing clinical trials, and writing practice guidelines that encourage the use of certain drugs.

Other Versions

No versions found

Links

PhilArchive

    This entry is not archived by us. If you are the author and have permission from the publisher, we recommend that you archive it. Many publishers automatically grant permission to authors to archive pre-prints. By uploading a copy of your work, you will enable us to better index it, making it easier to find.

    Upload a copy of this work     Papers currently archived: 103,836

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Prescription Data Mining and the Protection of Patients' Interests.David Orentlicher - 2010 - Journal of Law, Medicine and Ethics 38 (1):74-84.

Analytics

Added to PP
2011-11-16

Downloads
55 (#423,716)

6 months
5 (#826,666)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Five Un-Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.

Add more citations